{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:46:05Z","timestamp":1791215165291,"version":"4.1.0"},"reference-count":137,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes,  as well as the large genetic diversity between HCV strains. On the other hand, the use of  interferon-\u03b1-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development, and direct-acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens.<\/jats:p>","DOI":"10.3390\/v7102868","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T11:05:55Z","timestamp":1443524755000},"page":"5206-5224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance"],"prefix":"10.3390","volume":"7","author":[{"given":"Auda","family":"Eltahla","sequence":"first","affiliation":[{"name":"Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences,  Faculty of Medicine, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Luciani","sequence":"additional","affiliation":[{"name":"Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences,  Faculty of Medicine, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6046-9631","authenticated-orcid":false,"given":"Peter","family":"White","sequence":"additional","affiliation":[{"name":"School of Biotechnology and Biomolecular Sciences, Faculty of Science, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences,  Faculty of Medicine, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Bull","sequence":"additional","affiliation":[{"name":"Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences,  Faculty of Medicine, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Groeger","year":"2013","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/jvi.66.3.1476-1483.1992","article-title":"Internal ribosome entry site within hepatitis C virus RNA","volume":"66","author":"Iizuka","year":"1992","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1128\/jvi.67.6.3338-3344.1993","article-title":"Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism","volume":"67","author":"Wang","year":"1993","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1128\/JVI.00201-09","article-title":"Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo","volume":"83","author":"Cuevas","year":"2009","journal-title":"J. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.00694-10","article-title":"Viral mutation rates","volume":"84","author":"Sanjuan","year":"2010","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-\u03b1 therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/jvi.66.5.3225-3229.1992","article-title":"Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution","volume":"66","author":"Martell","year":"1992","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature04388","article-title":"Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population","volume":"439","author":"Vignuzzi","year":"2005","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus\u201415 Years on","volume":"85","author":"Simmonds","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1073\/pnas.87.6.2057","article-title":"Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups","volume":"87","author":"Miller","year":"1990","journal-title":"Proc. Nat. Acad. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/j.1460-2075.1996.tb00329.x","article-title":"Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"15","author":"Behrens","year":"1996","journal-title":"EMBO J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1006\/viro.1996.8357","article-title":"Hepatitis C virus NS5B protein is a membrane-associated phosphoprotein with a predominantly perinuclear localization","volume":"227","author":"Hwang","year":"1997","journal-title":"Virology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/JVI.73.2.1649-1654.1999","article-title":"Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli","volume":"73","author":"Ferrari","year":"1999","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15479","DOI":"10.1074\/jbc.273.25.15479","article-title":"RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region","volume":"273","author":"Yamashita","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/1087057113489883","article-title":"A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virus RNA polymerase","volume":"18","author":"Eltahla","year":"2013","journal-title":"J. Biomol. Screen"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"96","author":"Bressanelli","year":"1999","journal-title":"Proc. Nat. Acad. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/13305","article-title":"Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site","volume":"6","author":"Lesburg","year":"1999","journal-title":"Nat. Struct. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0969-2126(00)80031-3","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"7","author":"Ago","year":"1999","journal-title":"Structure"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/35065653","article-title":"A mechanism for initiating RNA-dependent RNA polymerization","volume":"410","author":"Butcher","year":"2001","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/hep.20742","article-title":"Viral and host factors in early hepatitis C virus infection","volume":"42","author":"Mosley","year":"2005","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1128\/JVI.76.7.3482-3492.2002","article-title":"Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides","volume":"76","author":"Bressanelli","year":"2002","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1074\/jbc.M410191200","article-title":"A relaxed discrimination of 2'-O-methyl-GTP relative to GTP between de novo and elongative RNA synthesis by the hepatitis C RNA-dependent RNA polymerase NS5B","volume":"280","author":"Dutartre","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1128\/jvi.71.11.8416-8428.1997","article-title":"Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity","volume":"71","author":"Lohmann","year":"1997","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/JVI.74.2.851-863.2000","article-title":"De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus","volume":"74","author":"Luo","year":"2000","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/JVI.74.4.2017-2022.2000","article-title":"De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase","volume":"74","author":"Zhong","year":"2000","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/viro.2001.1039","article-title":"De novo initiation of viral RNA-dependent RNA synthesis","volume":"287","author":"Kao","year":"2001","journal-title":"Virology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"32906","DOI":"10.1074\/jbc.M110.151316","article-title":"Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis","volume":"285","author":"Harrus","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.1128\/JVI.00459-12","article-title":"Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405","volume":"86","author":"Scrima","year":"2012","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: An update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: Management of hepatitis C virus infection","volume":"55","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: Efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Inf. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bartenschlager, R., and Vogt, P.K. (2013). Hepatitis C Virus: From Molecular Virology to Antiviral Therapy, Springer.","DOI":"10.1007\/978-3-642-27340-7"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2424","article-title":"The design of drugs for HIV and HCV","volume":"6","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_43","unstructured":"Delang, L., Neyts, J., Vliegen, I., Abrignani, S., Neddermann, P., and de Francesco, R. (2013). Hepatitis C Virus: From Molecular Virology to Antiviral Therapy, Springer."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1128\/AAC.00533-08","article-title":"Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors","volume":"52","author":"Herlihy","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3851\/IMP2088","article-title":"Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase","volume":"17","author":"Pawlotsky","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat. Med."},{"key":"ref_47","first-page":"223A","article-title":"Valopicitabine (NM283) plus PEG-interferon in treatment-naive hepatitis C patients with HCV genotype-1 infection: HCV RNA clearance during 24 weeks of treatment","volume":"44","author":"Lawitz","year":"2006","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Pockros, P., Jensen, D., Tsai, N., Taylor, R., Ramji, A., Cooper, C., Dickson, R., Tice, A., Stande, S., and Ipe, D. (2011). First SVR data with the nucleoside analogue polymerase inhibitor Mericitabine (RG7128) combined with Peginterferon\/Ribavirin in treatment-naive HCV g1\/4 patients: interim analysis from the JUMP-C trial. J. Hepatol., 54.","DOI":"10.1016\/S0168-8278(11)61361-5"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1016\/S0168-8278(12)61423-8","article-title":"Interferon-free treatment with a combination of Mericitabine and Danoprevir with or without Ribavirin in treatment-naive HCV genotype 1-infected patients","volume":"56","author":"Gane","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d-2\u02b9-deoxy-2\u02b9-\u03b1-fluoro-2\u02b9-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1126\/science.1259210","article-title":"Structural basis for RNA replication by the hepatitis C virus polymerase","volume":"347","author":"Appleby","year":"2015","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1\u20136 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.26275","article-title":"JUMP-C: A randomized trial of mericitabine plus pegylated interferon \u03b1-2a\/ribavirin for 24 weeks in treatment-na\u00efve HCV genotype 1\/4 patients","volume":"58","author":"Pockros","year":"2013","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep.26274","article-title":"PROPEL: A randomized trial of mericitabine plus peginterferon \u03b1-2a\/ribavirin therapy in treatment-na\u00efve HCV genotype 1\/4 patients","volume":"58","author":"Wedemeyer","year":"2013","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.12588","article-title":"Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study","volume":"35","author":"Gane","year":"2015","journal-title":"Liver Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1016\/S0168-8278(14)61470-7","article-title":"An interferon-and ribavirin-free 12-week regimen of once-daily VX-135 and daclatasvir in treatment-na\u00efve patients with genotype 1 HCV infection","volume":"60","author":"Gane","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Arnold, J.J., Sharma, S.D., Feng, J.Y., Ray, A.S., Smidansky, E.D., Kireeva, M.L., Cho, A., Perry, J., Vela, J.E., and Park, Y. (2012). Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides.","DOI":"10.1371\/journal.ppat.1003030"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jmb.2011.10.001","article-title":"An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors","volume":"414","author":"Simister","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1128\/AAC.02799-13","article-title":"Nonnucleoside inhibitors of norovirus RNA polymerase: Scaffolds for rational drug design","volume":"58","author":"Eltahla","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2008.12.028","article-title":"Substituted imidazopyridines as potent inhibitors of HCV replication","volume":"50","author":"Vliegen","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00307-11","article-title":"Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase","volume":"55","author":"Shih","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.22717","article-title":"HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus","volume":"49","author":"Kneteman","year":"2009","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1469-0691.2010.03430.x","article-title":"New HCV therapies on the horizon","volume":"17","author":"Vermehren","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","article-title":"New horizons in hepatitis C antiviral therapy with direct-acting antivirals","volume":"58","author":"Aghemo","year":"2013","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1053\/j.gastro.2011.08.051","article-title":"Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection","volume":"141","author":"Zeuzem","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Beaulieu, P., Anderson, P., Brochu, C., Bos, M., Cordingley, M., Duan, J., Garneau, M., Lagrace, L., Marquis, M., and McKercher, G. (2012). Preclinical characterization of the hepatitis C virus NS5B polymerase non-nucleoside inhibitor BI 207127. J. Hepatol., 56.","DOI":"10.1016\/S0168-8278(12)60834-4"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1128\/AAC.00245-12","article-title":"TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage","volume":"56","author":"Devogelaere","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/AAC.02495-13","article-title":"Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase","volume":"58","author":"Lemm","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"33456","DOI":"10.1074\/jbc.M114.613653","article-title":"Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase","volume":"289","author":"Rigat","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"McPhee, D., Falk, P., Fracasso, P., Lemm, J., Liu, M., Kirk, M., Hernandez, D., Cooney, E., Hughes, E., and Gao, M. (2012). Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-alfa and ribavirin. J. Hepatol., 56.","DOI":"10.1016\/S0168-8278(12)61206-9"},{"key":"ref_79","unstructured":"Poordad, F., Sievert, W., Mollison, L., Br\u00e4u, N., Levin, J., Sepe, T., Lee, S., Boyer, N., and Bronowicki, J. (,  2014). All-Oral, Fixed-Dose Combination Therapy with Daclatasvir\/Asunaprevir\/Beclabuvir for Non-Cirrhotic Patients with Chronic HCV Genotype 1 Infection: Unity-1 Phase 3 SVR12 Results. Proceedings of 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bmcl.2003.10.067","article-title":"Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides","volume":"14","author":"Chan","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.02052-12","article-title":"Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase","volume":"57","author":"Fenaux","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/S0168-8278(09)60942-9","article-title":"Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals","volume":"50","author":"Cooper","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1021\/jm8014537","article-title":"Discovery of (R)-6-cyclopentyl-6-(2-(2, 6-diethylpyridin-4-yl) ethyl)-3-((5, 7-dimethyl-[1,2,4] triazolo [1, 5-a] pyrimidin-2-yl) methyl)-4-hydroxy-5, 6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor","volume":"52","author":"Li","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/AAC.01599-08","article-title":"Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"53","author":"Shi","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1016\/S0168-8278(09)61054-0","article-title":"Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1","volume":"50","author":"Jacobson","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.05438-11","article-title":"Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir","volume":"56","author":"Yi","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1128\/JVI.02628-05","article-title":"Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus","volume":"80","author":"Kang","year":"2006","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1128\/AAC.03052-14","article-title":"Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor","volume":"58","author":"Jiang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MEG.0000000000000084","article-title":"VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection","volume":"26","author":"Sulkowski","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.24342","article-title":"Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients","volume":"54","author":"Wagner","year":"2011","journal-title":"Hepatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"38322","DOI":"10.1074\/jbc.M205566200","article-title":"Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase","volume":"277","author":"Dhanak","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61410-X","article-title":"12-week interferon-free regimen of ABT-450\/R+ ABT-333+ ribavirin achieved SVR 12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders","volume":"56","author":"Poordad","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Lawitz, E., Rodriquez-Torres, M., Rustgi, V.K., Hassanein, T., Rahimy, M.H., Crowley, C.A., Freddo, J.L., Muir, A., and McHutchison, J. (2010). Safety and antiviral activity of ANA598 in combination with pegylated interferon \u03b12a plus ribavirin in treatment-naive genotype-1 chronic HCV patients. J. Hepatol., 52.","DOI":"10.1016\/S0168-8278(10)61200-7"},{"key":"ref_96","first-page":"849A","article-title":"Interferon-free regimen containing setrobuvir in combination with ritonavir-boosted danoprevir and ribavirin with or without mericitabine in HCV genotype 1 treatment-naive patients: Interim results from the ANNAPURNA study","volume":"58","author":"Jensen","year":"2013","journal-title":"Hepatology"},{"key":"ref_97","first-page":"1164A","article-title":"In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance","volume":"48","author":"Thompson","year":"2008","journal-title":"Hepatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jac\/dkn085","article-title":"Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients","volume":"61","author":"Seshaadri","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1021\/jm060168g","article-title":"Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site","volume":"49","author":"Gopalsamy","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1128\/AAC.00669-08","article-title":"1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors","volume":"52","author":"Nyanguile","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/med.21271","article-title":"Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: Ten years of research","volume":"33","author":"Haudecoeur","year":"2013","journal-title":"Med. Res. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00238-08","article-title":"Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796","volume":"52","author":"Howe","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Lawitz, E., Jacobson, I., Godofsky, E., Foster, G.R., and Filisiak, R. (2011). A Phase 2b Trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)\/PEG\/RBV to 48 weeks treatment with PEG\/RBV for chronic genotype 1 HCV infection. J. Hepatol., 54.","DOI":"10.1016\/S0168-8278(11)60447-9"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","article-title":"The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C","volume":"55","author":"Zeuzem","year":"2012","journal-title":"Hepatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2015.05.011","article-title":"In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying\/preventing the development of drug resistance","volume":"120","author":"Vliegen","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"13225","DOI":"10.1128\/JVI.77.24.13225-13231.2003","article-title":"Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase","volume":"77","author":"Tomei","year":"2003","journal-title":"J. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/nar\/gkh160","article-title":"Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template\/primer substrate","volume":"32","author":"McKercher","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"29765","DOI":"10.1074\/jbc.M505423200","article-title":"Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site","volume":"280","author":"Volpari","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.antiviral.2012.12.027","article-title":"Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase","volume":"97","author":"Winquist","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.1074\/jbc.M413410200","article-title":"Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors","volume":"280","author":"Biswal","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jmb.2006.05.074","article-title":"Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition","volume":"361","author":"Biswal","year":"2006","journal-title":"J. Mol. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1128\/AAC.03699-14","article-title":"Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders","volume":"58","author":"Eltahla","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e39163","DOI":"10.1371\/journal.pone.0039163","article-title":"The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function","volume":"7","author":"Hebner","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1128\/JVI.00386-12","article-title":"Structure of hepatitis C virus polymerase in complex with primer-template RNA","volume":"86","author":"Mosley","year":"2012","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/jm050859x","article-title":"SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase","volume":"49","author":"Powers","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"15517","DOI":"10.1074\/jbc.M808889200","article-title":"Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus","volume":"284","author":"Hang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/JVI.78.2.938-946.2004","article-title":"Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides","volume":"78","author":"Tomei","year":"2004","journal-title":"J. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"16602","DOI":"10.1074\/jbc.M210891200","article-title":"Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives","volume":"278","author":"Gu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.13.2.223","article-title":"Clinical significance of hepatitis C virus genotypes","volume":"13","author":"Zein","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/jm401401n","article-title":"On the History of Hepatitis C Virus Cell Culture Systems: Miniperspective","volume":"57","author":"Lohmann","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.antiviral.2013.08.018","article-title":"In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons","volume":"100","author":"Yu","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.bbapap.2011.05.006","article-title":"RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities","volume":"1814","author":"May","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.virol.2012.03.025","article-title":"Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a","volume":"429","author":"Wong","year":"2012","journal-title":"Virology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1128\/JVI.01543-06","article-title":"Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors","volume":"81","author":"Pauwels","year":"2007","journal-title":"J. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0168-8278(09)60957-0","article-title":"Preclinical potency, pharmacokinetic and AMDE characterization of ABT-333, a novel non-nucleoside HCV polymerase inhibitor","volume":"50","author":"Maring","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Paolucci, S., Fiorina, L., Mariani, B., Gulminetti, R., Novati, S., Barbarini, G., Bruno, R., and Baldanti, F. (2013). Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients. Virol J., 10.","DOI":"10.1186\/1743-422X-10-355"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/hep.22773","article-title":"Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy","volume":"49","author":"Gaudieri","year":"2009","journal-title":"Hepatology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/jvh.12051","article-title":"The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank","volume":"20","author":"Alves","year":"2013","journal-title":"J. Viral. Hepat."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na\u00efve patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"HCV variants with decreased sensitivity to direct acting antivirals were rarely observed in DAA-na\u00efve patients prior to treatment","volume":"87","author":"Bartels","year":"2012","journal-title":"J. Virol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Margeridon-Thermet, S., Le Pogam, S., Li, L., Liu, T.F., Shulman, N., Shafer, R.W., and Najera, I. (2014). Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105569"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3851\/IMP2821","article-title":"Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C","volume":"20","author":"Applegate","year":"2014","journal-title":"Antivir. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/JVI.06627-11","article-title":"Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing","volume":"86","author":"Lauck","year":"2012","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Nasu, A., Marusawa, H., Ueda, Y., Nishijima, N., Takahashi, K., Osaki, Y., Yamashita, Y., Inokuma, T., Tamada, T., and Fujiwara, T. (2011). Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024907"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"Powdrill","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"39260","DOI":"10.1074\/jbc.M506407200","article-title":"Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase","volume":"280","author":"Kukolj","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2014.02.011","article-title":"Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?","volume":"105","author":"Schneider","year":"2014","journal-title":"Antivir. Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/10\/2868\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:27Z","timestamp":1760215767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/10\/2868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":137,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10]]}},"alternative-id":["v7102868"],"URL":"https:\/\/doi.org\/10.3390\/v7102868","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}